Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE

Claudio Ceconi, Gloria Francolini, Adriana Olivares, Laura Comini, Tiziana Bachetti, Roberto Ferrari

Research output: Contribution to journalArticle

Abstract

The angiotensin-converting enzyme (ACE) has two natural substrates and two catalytic domains: one cleaving angiotensin I and one inactivating bradykinin. The aim of this study was to investigate the comparative binding affinity of ACE inhibitors for the two binding sites of human endothelial ACE. In vitro binding assays were performed to test the ability of bradykinin, angiotensin I, or various ACE inhibitors (enalaprilat, perindoprilat, quinaprilat, ramiprilat, and trandolaprilat) to displace a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue, from ACE binding sites. The calculated IC50 values for the ACE inhibitors were in the nanomolar range, while those for the natural substrates were in the micromolar range. The bradykinin/angiotensin I selectivity ratios calculated from double displacement experiments were: perindoprilat, 1.44; ramiprilat, 1.16; quinaprilat, 1.09; trandolaprilat, 1.08; enalaprilat, 1.00. The ACE inhibitors generally had higher affinity for the bradykinin than the angiotensin I binding sites, supporting the idea that these agents are primarily inhibitors of bradykinin degradation, and secondarily inhibitors of angiotensin II production. Perindoprilat had the highest selectivity for bradykinin versus angiotensin I binding sites, and enalaprilat has the lowest. These results indicate that there are differences in the affinity of ACE inhibitors toward sites for bradykinin degradation, which could lead to differences in efficacy in cardiovascular disease.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalEuropean Journal of Pharmacology
Volume577
Issue number1-3
DOIs
Publication statusPublished - Dec 22 2007

Fingerprint

Bradykinin
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Angiotensin I
perindoprilat
Binding Sites
Enalaprilat
Lisinopril
Angiotensin II
Inhibitory Concentration 50
Catalytic Domain
Cardiovascular Diseases

Keywords

  • ACE
  • ACE inhibitor
  • Angiotensin I
  • Binding affinity
  • Bradykinin
  • Cardiovascular disease
  • HUVEC
  • Perindopril
  • Perindoprilat
  • Selectivity

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. / Ceconi, Claudio; Francolini, Gloria; Olivares, Adriana; Comini, Laura; Bachetti, Tiziana; Ferrari, Roberto.

In: European Journal of Pharmacology, Vol. 577, No. 1-3, 22.12.2007, p. 1-6.

Research output: Contribution to journalArticle

@article{ccb066a15ce448519504a36429c8b309,
title = "Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE",
abstract = "The angiotensin-converting enzyme (ACE) has two natural substrates and two catalytic domains: one cleaving angiotensin I and one inactivating bradykinin. The aim of this study was to investigate the comparative binding affinity of ACE inhibitors for the two binding sites of human endothelial ACE. In vitro binding assays were performed to test the ability of bradykinin, angiotensin I, or various ACE inhibitors (enalaprilat, perindoprilat, quinaprilat, ramiprilat, and trandolaprilat) to displace a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue, from ACE binding sites. The calculated IC50 values for the ACE inhibitors were in the nanomolar range, while those for the natural substrates were in the micromolar range. The bradykinin/angiotensin I selectivity ratios calculated from double displacement experiments were: perindoprilat, 1.44; ramiprilat, 1.16; quinaprilat, 1.09; trandolaprilat, 1.08; enalaprilat, 1.00. The ACE inhibitors generally had higher affinity for the bradykinin than the angiotensin I binding sites, supporting the idea that these agents are primarily inhibitors of bradykinin degradation, and secondarily inhibitors of angiotensin II production. Perindoprilat had the highest selectivity for bradykinin versus angiotensin I binding sites, and enalaprilat has the lowest. These results indicate that there are differences in the affinity of ACE inhibitors toward sites for bradykinin degradation, which could lead to differences in efficacy in cardiovascular disease.",
keywords = "ACE, ACE inhibitor, Angiotensin I, Binding affinity, Bradykinin, Cardiovascular disease, HUVEC, Perindopril, Perindoprilat, Selectivity",
author = "Claudio Ceconi and Gloria Francolini and Adriana Olivares and Laura Comini and Tiziana Bachetti and Roberto Ferrari",
year = "2007",
month = "12",
day = "22",
doi = "10.1016/j.ejphar.2007.07.061",
language = "English",
volume = "577",
pages = "1--6",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE

AU - Ceconi, Claudio

AU - Francolini, Gloria

AU - Olivares, Adriana

AU - Comini, Laura

AU - Bachetti, Tiziana

AU - Ferrari, Roberto

PY - 2007/12/22

Y1 - 2007/12/22

N2 - The angiotensin-converting enzyme (ACE) has two natural substrates and two catalytic domains: one cleaving angiotensin I and one inactivating bradykinin. The aim of this study was to investigate the comparative binding affinity of ACE inhibitors for the two binding sites of human endothelial ACE. In vitro binding assays were performed to test the ability of bradykinin, angiotensin I, or various ACE inhibitors (enalaprilat, perindoprilat, quinaprilat, ramiprilat, and trandolaprilat) to displace a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue, from ACE binding sites. The calculated IC50 values for the ACE inhibitors were in the nanomolar range, while those for the natural substrates were in the micromolar range. The bradykinin/angiotensin I selectivity ratios calculated from double displacement experiments were: perindoprilat, 1.44; ramiprilat, 1.16; quinaprilat, 1.09; trandolaprilat, 1.08; enalaprilat, 1.00. The ACE inhibitors generally had higher affinity for the bradykinin than the angiotensin I binding sites, supporting the idea that these agents are primarily inhibitors of bradykinin degradation, and secondarily inhibitors of angiotensin II production. Perindoprilat had the highest selectivity for bradykinin versus angiotensin I binding sites, and enalaprilat has the lowest. These results indicate that there are differences in the affinity of ACE inhibitors toward sites for bradykinin degradation, which could lead to differences in efficacy in cardiovascular disease.

AB - The angiotensin-converting enzyme (ACE) has two natural substrates and two catalytic domains: one cleaving angiotensin I and one inactivating bradykinin. The aim of this study was to investigate the comparative binding affinity of ACE inhibitors for the two binding sites of human endothelial ACE. In vitro binding assays were performed to test the ability of bradykinin, angiotensin I, or various ACE inhibitors (enalaprilat, perindoprilat, quinaprilat, ramiprilat, and trandolaprilat) to displace a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue, from ACE binding sites. The calculated IC50 values for the ACE inhibitors were in the nanomolar range, while those for the natural substrates were in the micromolar range. The bradykinin/angiotensin I selectivity ratios calculated from double displacement experiments were: perindoprilat, 1.44; ramiprilat, 1.16; quinaprilat, 1.09; trandolaprilat, 1.08; enalaprilat, 1.00. The ACE inhibitors generally had higher affinity for the bradykinin than the angiotensin I binding sites, supporting the idea that these agents are primarily inhibitors of bradykinin degradation, and secondarily inhibitors of angiotensin II production. Perindoprilat had the highest selectivity for bradykinin versus angiotensin I binding sites, and enalaprilat has the lowest. These results indicate that there are differences in the affinity of ACE inhibitors toward sites for bradykinin degradation, which could lead to differences in efficacy in cardiovascular disease.

KW - ACE

KW - ACE inhibitor

KW - Angiotensin I

KW - Binding affinity

KW - Bradykinin

KW - Cardiovascular disease

KW - HUVEC

KW - Perindopril

KW - Perindoprilat

KW - Selectivity

UR - http://www.scopus.com/inward/record.url?scp=35448931632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448931632&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2007.07.061

DO - 10.1016/j.ejphar.2007.07.061

M3 - Article

C2 - 17716647

AN - SCOPUS:35448931632

VL - 577

SP - 1

EP - 6

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -